medications
-
Health
The Hidden Risks of Stopping GLP-1 Medications for Cardiovascular Health
The meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists—a class of drugs that includes semaglutide (marketed as Ozempic and Wegovy)…
Read More » -
Health
GLP-1 medications and the search for broader life impacts beyond diabetes management
The rise of glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, Wegovy, and Mounjaro, has arguably been the most significant…
Read More » -
Lifestyle
The Intersection of GLP-1 Medications and Professional Sports: Performance Enhancer or Medical Treatment
The rapid rise of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has transcended the boundaries of chronic disease management…
Read More » -
Health
AI-Powered Social Listening Reveals Patient-Reported Symptoms of Popular GLP-1 Weight-Loss Medications
Artificial intelligence is giving researchers a new way to listen to what patients are saying about popular GLP-1 drugs, as…
Read More » -
Health
Weight Loss Medications Linked to Significant Drop in Physical Activity, New Study Reveals
A groundbreaking study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Illinois, has revealed a surprising and…
Read More » -
Health
New Large-Scale Study Raises Questions About Long-Term Safety of Common Irritable Bowel Syndrome Medications
A landmark study, spearheaded by researchers at Cedars-Sinai Health Sciences University, is casting a significant shadow of doubt over the…
Read More »
